MicroPort CardioFlow Medtech Corporation
MicroPort CardioFlow Medtech Corporation Fundamental Analysis
MicroPort CardioFlow Medtech Corporation (2160.HK) shows weak financial fundamentals with a PE ratio of 244.63, profit margin of 1.32%, and ROE of 0.22%. The company generates $0.4B in annual revenue with moderate year-over-year growth of 7.54%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 36.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 2160.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak2160.HK struggles to generate sufficient returns from assets.
Valuation Score
Weak2160.HK trades at a premium to fair value.
Growth Score
Excellent2160.HK delivers strong and consistent growth momentum.
Financial Health Score
Excellent2160.HK maintains a strong and stable balance sheet.
Profitability Score
Weak2160.HK struggles to sustain strong margins.
Key Financial Metrics
Is 2160.HK Expensive or Cheap?
P/E Ratio
2160.HK trades at 244.63 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 2160.HK's PEG of 2.52 indicates potential overvaluation.
Price to Book
The market values MicroPort CardioFlow Medtech Corporation at 0.54 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -14.59 times EBITDA. This is generally considered low.
How Well Does 2160.HK Make Money?
Net Profit Margin
For every $100 in sales, MicroPort CardioFlow Medtech Corporation keeps $1.32 as profit after all expenses.
Operating Margin
Core operations generate -8.25 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $0.22 in profit for every $100 of shareholder equity.
ROA
MicroPort CardioFlow Medtech Corporation generates $0.18 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
MicroPort CardioFlow Medtech Corporation generates limited operating cash flow of $-27.76M, signaling weaker underlying cash strength.
Free Cash Flow
MicroPort CardioFlow Medtech Corporation generates weak or negative free cash flow of $-185.94M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.39 in free cash annually.
FCF Yield
2160.HK converts -14.62% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
244.63
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.52
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.54
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.34
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.13
vs 25 benchmark
Current Ratio
Current assets to current liabilities
6.94
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.002
vs 25 benchmark
ROA
Return on assets percentage
0.002
vs 25 benchmark
ROCE
Return on capital employed
-0.01
vs 25 benchmark
How 2160.HK Stacks Against Its Sector Peers
| Metric | 2160.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 244.63 | 28.54 | Worse (Expensive) |
| ROE | 0.22% | 738.00% | Weak |
| Net Margin | 1.32% | -43982.00% (disorted) | Weak |
| Debt/Equity | 0.13 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 6.94 | 2806.01 | Strong Liquidity |
| ROA | 0.18% | -14624.00% (disorted) | Weak |
2160.HK outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews MicroPort CardioFlow Medtech Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-99.09%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
99.98%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
99.96%
Industry Style: Defensive, Growth, Innovation
High Growth